Literature DB >> 8108132

A versatile expression vector for the in vitro study of protein-protein interactions: characterization of E47 mutant proteins.

T Hainzl1, T Boehm.   

Abstract

Several mutants of the E47 protein, a member of the family of basic/helix-loop-helix (b-HLH) transcriptional regulators, were examined for their ability to homo- and heterodimerize with the protein product of the T-cell oncogene tal-1/SCL. For this purpose, a novel bacterial expression system was developed in which proteins are expressed as fusions appended to glutathione-S-transferase via a thrombin cleavage site and either one or four protein kinase recognition sites embedded in a glycine-rich domain. Since the interaction domain can be purified away from the glutathione-S-transferase moiety and the radioactive label is located in a flexible N-terminal tag, protein folding should occur normally. Our studies with E47 proteins prepared in this system indicate that the ratio between E47 homodimers and E47/tal-1 heterodimers can dramatically shift upon subtle mutations in the loop region and the second helix of the E47 protein. This unexpected results suggests a novel mechanism to alter the equilibrium between different transactivating protein complexes of the b-HLH class.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8108132

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  Expression of peptides encoded by exons in cloned mammalian DNA.

Authors:  S Kreissig; K Schüddekopf; N Dear; T Boehm
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

2.  Neomycin- and hygromycin-resistance expression cassettes containing an artificial triple-helix site and a synthetic lac operator facilitate restriction endonuclease cleavage at pre-defined sites and recovery of specific fragments from mammalian genomes.

Authors:  M C Nehls; S Krause; T Boehm
Journal:  Mamm Genome       Date:  1994-03       Impact factor: 2.957

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.